Dupimulab reduced exacerbations and improved lung functions in patients with moderate-to-severe asthma and prior exacerbations: LIBERTY ASTHMA TRAVERSE study.

Sanofi and Regeneron Pharmaceuticals, Inc

Dupilumab reduced impact of severe exacerbations on lung function in patients with moderate-to-severe type 2 asthma

Background: Severe asthma exacerbations increase the risk of accelerated lung function decline. This analysis examined the effect of dupilumab on forced expiratory volume in 1 second (FEV1 ) in patients with moderate-to-severe asthma and elevated type 2 biomarkers from phase 3 LIBERTY ASTHMA QUEST (NCT02414854). Methods: Changes from baseline in pre- and post-bronchodilator (BD) FEV1 and 5-item Asthma Control Questionnaire (ACQ-5) scores were assessed in patients with elevated type 2 biomarkers at baseline (type 2-150/25: eosinophils ≥150 cells/μL and/or fractional exhaled nitric oxide [FeNO] ≥25 ppb; type 2-300/25: eosinophils ≥300 cells/μL and/or FeNO ≥25 ppb), stratified as exacerbators (≥1 severe exacerbation during the study) or non-exacerbators. Results: In exacerbators and non-exacerbators, dupilumab increased pre-BD FEV1 by Week 2 vs placebo; differences were maintained to Week 52 (type 2-150/25: LS mean difference (LSMD) vs placebo: 0.17 L (95% CI: 0.10-0.24) and 0.17 L (0.12-0.23); type 2-300/25: 0.22 L (0.13-0.30) and 0.21 L (0.15-0.28), in exacerbators and non-exacerbators, respectively (P<.0001). Similar trends were seen for post-BD FEV1 . Dupilumab vs placebo also showed significantly greater improvements in post-BD FEV1 0-42 days after first severe exacerbation in type 2-150/25 (LSMD vs placebo: 0.13 L [0.06-0.20]; P=.006) and type 2-300/25 (0.14 L [0.06-0.22]; P=.001) patients. ACQ-5 improvements were greater with dupilumab vs placebo in both groups. Conclusion: Dupilumab treatment led to improvements in lung function independent of exacerbations and appeared to reduce the impact of exacerbations on lung function in patients who experienced a severe exacerbation during the study

Dupilumab reduced severe exacerbation rates and improved pre-bronchodilator Fev 1 in patients with moderate-to-severe asthma regardless of exacerbation history of 蠅1, 蠅2, or 蠅3 prior exacerbations: Liberty Asthma Traverse

This is the author accepted manuscript. The final version is available from the American Thoracic Society via the DOI in this record Sanofi and Regeneron Pharmaceuticals, Inc

Dupilumab efficacy in VOYAGE pediatric patients with uncontrolled, moderate-to- severe type 2 inflammatory asthma by allergen sensitization status

Phipatanakul W, Papadopoulos NG, Hernandez-Trujillo V, et al. Dupilumab efficacy in VOYAGE pediatric patients with uncontrolled, moderate-to- severe type 2 inflammatory asthma by allergen sensitization status. In: Abstracts from the European Academy of Allergy and Clinical Immunology Hybrid Congress, 1-3 July 2022. Vol 78. Hoboken: Wiley; 2023: 5-6

Dupilumab efficacy in VOYAGE pediatric patients with uncontrolled, moderate-to-severe type 2 inflammatory asthma by allergen sensitization status

Phipatanakul W, Papadopoulos NG, Hernandez-Trujillo V, et al. Dupilumab efficacy in VOYAGE pediatric patients with uncontrolled, moderate-to-severe type 2 inflammatory asthma by allergen sensitization status. Allergologie. 2022;45(8):604